Aquestive Therapeutics Inc (NASDAQ:AQST)’s share price traded up 14.2% during trading on Monday . The stock traded as high as $7.89 and last traded at $8.90, 100,693 shares traded hands during mid-day trading. A decline of 89% from the average session volume of 897,614 shares. The stock had previously closed at $7.79.
AQST has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $14.00 target price (up from $12.00) on shares of Aquestive Therapeutics in a research note on Monday. Wedbush reiterated a “buy” rating and issued a $37.00 price target on shares of Aquestive Therapeutics in a research note on Monday. Zacks Investment Research raised shares of Aquestive Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Monday, November 11th. Finally, ValuEngine lowered shares of Aquestive Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $18.40.
The firm has a 50-day moving average of $5.14 and a 200-day moving average of $4.19. The firm has a market capitalization of $221.48 million, a P/E ratio of -3.13 and a beta of 2.70.
Aquestive Therapeutics Company Profile (NASDAQ:AQST)
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Recommended Story: What is a stock split?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.